<span item_type="fundamental" item_id="cc497f5db17f13202e885a883233c6f0" counter_id="ST/US/ICUCW" env="prod"></span><span item_type="announcement" item_id="549089683981599105" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 631 K.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.58.</p><p></p><h3>Segment Revenue</h3><ul><li>Net revenue for the three months ended June 30, 2025, was $338,000, compared to $0 for the same period in 2024. For the six months ended June 30, 2025, net revenue was $631,000, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross profit for the three months ended June 30, 2025, was $311,000, with a gross margin of approximately 92%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li><li>Loss from operations for the three months ended June 30, 2025, was -$1,756,000, compared to -$4,669,000 for the same period in 2024, representing a 63% improvement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li><li>Total operating expenses for the three months ended June 30, 2025, were $2,067,000, a decrease of 56% from $4,669,000 in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025, was -$5,661,000, compared to -$6,312,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li><li>Net cash provided by financing activities for the six months ended June 30, 2025, was $10,144,000, compared to $7,315,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company plans to continue the development of its adult Selective Cytopheretic Device (SCD) and invest in the commercialization of QUELIMMUNE, with a focus on expanding its customer base and increasing revenue from product sales.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li><li>The company acknowledges the need for additional capital to fund operations and complete the regulatory approval process for its products. It plans to seek additional funding through equity or debt financing, collaborations, or other strategic transactions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1831868/000183186825000007/icu-20250630.htm"></span></li></ul>

SEASTAR MEDICAL HOLDING CORP C/WTS 28/10/2027 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 631 K